MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] --
 QUICK SEARCH:   [advanced]


     


Molecular Pharmacology Fast Forward
First published on July 12, 2007; DOI: 10.1124/mol.107.037358


This Article
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow All Versions of this Article:
mol.107.037358v1
72/4/947    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kotokorpi, P.
Right arrow Articles by Mode, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kotokorpi, P.
Right arrow Articles by Mode, A.


Received for publication April 23, 2007.
Revised July 12, 2007.
Accepted for publication July 12, 2007.

Physiological differences between human and rat primary hepatocytes in response to LXR activation by GW3965

Pia Kotokorpi 1, Ewa Ellis 2, Paolo Parini 3, Lisa-Mari Nilsson 3, Stephen Strom 2, Knut Steffensen 4*, Jan-Ake Gustafsson 1, Agneta Mode 1

1 Karolinska Institutet 2 University of Pittsburgh 3 Karolinska Institutet at Karolinska University Hospital Huddinge 4 Karolinska Institutet at NOVUM

* Address correspondence to: E-mail: knut.steffensen{at}biosci.ki.se

Abstract

The liver is central for the maintenance of glucose and lipid homeostasis, and liver X receptors (LXRs) are key regulators of expression of the genes involved. So far, effects of activation of LXR in human hepatocytes have not been well characterized. Here we show that treatment of primary human hepatocytes with the synthetic LXR ligand, GW3965, results in reduced output of bile acids and VLDL-triglycerides and induced expression of adipose differentiation-related protein accompanied by increased lipid storage. Genome wide expression profiling identified novel human LXR target genes in the glycolytic and lipogenic pathways and indicated that LXR activation reduced hepatic insulin sensitivity. Comparative experiments showed significant differences in the response to GW3965 between human and rat hepatocytes, raising the question as to how well rodent models reflect the human situation. In summary, the risk of hepatic steatosis upon pharmaceutical targeting of LXR may be a particularly serious consequence in humans.


Key words: Insulin, Comparative genome analyses, Regulation of gene expression, Regulation - transcriptional, Cholesterol metabolism/lipoproteins





Home Help [Feedback] [For Subscribers] [Archive] [Search] --
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2007 by the American Society for Pharmacology and Experimental Therapeutics